Clinical Protocol: Administration of Neomycin Resistance Gene-Marked EBV-Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving a Bone Marrow Transplant for Relapsed EBV-Positive Hodgkin Disease.
- 1 July 2000
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (10) , 1465-1475
- https://doi.org/10.1089/10430340050057530
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Control mechanisms of Epstein-Barr virus persistenceSeminars in Virology, 1994
- Epstein-Barr virus strategy in normal and neoplastic B cellsCell, 1994
- Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.Proceedings of the National Academy of Sciences, 1989
- Immunobiology of CR2, the B Lymphocyte Receptor for Epstein-Barr Virus and the C3d Complement FragmentAnnual Review of Immunology, 1988
- Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus.Journal of Clinical Oncology, 1987